CDK4/6 Inhibitors in Practice

Efficacy of CDK4/6 Inhibitors: Two Different Settings

Are All the CDK4/6 Inhibitors Created Equal?

CDK4/6 Inhibitors: Consistency of Response

Clinical Endpoints of Interest in MBC Trials

PALOMA-3: Global QoL, Functioning, and Symptoms

FALCON Trial: Subgroup Analysis

MONARCH-3: PFS Bone-Only Disease

Future Questions

CDK4/6 Inhibitors and Clinical Profiles

Unanswered Questions

Clinical Considerations

Future Studies

Concluding Remarks

CDK4/6 Inhibitors in Premenopausal Patients

PALOMA-3: Palbociclib Plus Fulvestrant vs Fulvestrant

CDK4/6 Inhibitors in Premenopausal Women Clinical Considerations

MONARCH-2: Abemaciclib Plus Fulvestrant vs Fulvestrant

MONALEESA-7: Ribociclib Plus Goserelin and Tamoxifen/AI vs Goserelin and Tamoxifen/AI

Concluding Remarks

Impact of CDK4/6 Inhibitors on the Treatment Sequence

CDK4/6 Inhibitors: Providing Therapeutic Benefit

CDK4/6 Inhibitors: Unanswered Questions Remain Regarding Sequencing

PALOMA-3: Postprogression Therapies

Future Studies Are Needed

Concluding Remarks

Selecting the Right Endocrine Partner for CDK 4/6 Inhibitors

The Cell Cycle and CDKs

CDK4/6 Inhibitors: Differences in ET Strategy in Clinical Trials

PARSIFAL Trial

Concluding Remarks

Resistance to CDK4/6 Inhibitors

Mechanisms of Resistance to CDK4/6 Inhibitors

Primary Resistance

Secondary Resistance: CDK2 Activation

Secondary Resistance: RB1 Mutation

Secondary Resistance: Amplification of CDK6

Implications to Clinical Practice

Resistance to CDK4/6 Inhibitors: Clinical Considerations

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)